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Abstract
The hepatocyte growth factor (HGF) receptor c-Met is a
tyrosine kinase receptor with established oncogenic
properties. We have previously shown that c-Met is
usually overexpressed in esophageal adenocarcinoma
(EA), yet the implications of c-Met inhibition in EA
remain unknown. Three c-Met–overexpressing EA cell
lines (Seg-1, Bic-1, and Flo-1) were used to examine
the effects of a c-Met–specific small molecule in-
hibitor (PHA665752) on cell viability, apoptosis, mo-
tility, invasion, and downstream signaling pathways.
PHA665752 demonstrated dose-dependent inhibition
of constitutive and/or HGF-induced phosphorylation
of c-Met, which correlated with reduced cell viability
and inhibition of extracellular regulated kinase 1/2
phosphorylation in all three EA cell lines. In contrast,
PHA665752 induced apoptosis and reduced motility
and invasion in only one EA cell line, Flo-1. Interest-
ingly, Flo-1 was the only cell line in which phosphati-
dylinositol 3-kinase (PI3K)/Akt was induced following
HGF stimulation. The PI3K inhibitor LY294002 pro-
duced effects equivalent to those of PHA665752 in
these cells. We conclude that inhibition of c-Met may be
a useful therapeutic strategy for EA. Factors other than
receptor overexpression, such as c-Met–dependent
PI3K/Akt signaling, may be predictive of an individual
tumor’s response to c-Met inhibition.
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Introduction
Esophageal adenocarcinoma (EA) is a highly aggressive
malignancy with propensity for early local invasion and
systemic metastasis. The incidence of EA is increasing rap-
idly, and EA currently represents the most common histo-
logic type of esophageal cancer in the United States [1,2].
Despite advances in diagnosis and treatment, the overall
5-year survival remains approximately 14% [3,4]. The rising
incidence of EA and the dismal prognosis associated
with current treatment strategies warrant a search for inno-
vative therapies.
The hepatocyte growth factor (HGF) receptor c-Met is a
tyrosine kinase receptor with established oncogenic properties.
Activation of c-Met results in phosphorylation of the receptor
that leads to the recruitment of adaptor proteins and to the
subsequent activation of various signal transducers, including
phosphatidylinositol 3-kinase (PI3K) and extracellular regu-
lated kinase (ERK) 1/2, resulting ultimately in the stimula-
tion of growth, survival, motility, and invasion in certain cell
types [5]. c-Met is known to contribute to these properties of
malignant cells in a variety of human tumors, including lung
cancer [6–8], pancreatic cancer [9], ovarian cancer [10], glioma
[11], and gastric cancer [12], but the role of c-Met in EA remains
poorly defined.
Herrera et al. [13] and Miller et al. [14] have recently shown
that c-Met is overexpressed in EA compared to normal esoph-
ageal squamous epithelium and Barrett’s esophagus columnar
epithelium without dysplasia, suggesting that c-Met may be an
attractive candidate for targeted therapy in EA. In the present
study, we investigated the effects of PHA665752, a small
molecule inhibitor specific for c-Met kinase [15], on EA cell vi-
ability, apoptosis, motility, invasion, and downstream signaling
pathways. Our findings demonstrate variability in the response
of EA cell lines to c-Met inhibition, suggesting that factors other
than receptor overexpression may determine the response of
an individual neoplasm to c-Met inhibition.
Materials and Methods
Cell Lines
Three human EA-derived cell lines (Seg-1, Bic-1, and Flo-1)
have been previously described [16]. A549 is a human-derived
non–small cell lung cancer (NSCLC) cell line previously shown
to be c-Met–responsive [17]. Seg-1 was maintained in RPMI
1640 medium, and Bic-1, Flo-1, and A549 were maintained in
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DMEM (BioWhittaker, Walkersville, MD). The medium was
supplemented with 10% fetal bovine serum (Atlanta Bio-
logicals, Norcross, GA), 1% penicillin/streptomycin, and 1%
L-glutamine (Invitrogen, Carlsbad, CA), and cells were prop-
agated in a humidified environment at 37jC with 5% CO2.
Antibodies and Reagents
For immunoblotting, anti–phosho-Met1230/1234/1235 was
purchased from BioSource International, Inc. (Camarillo,
CA), and anti–phospho ERK and anti-ERK antibodies were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). Anti–phospho-AktSer473 and anti-Akt antibodies were
purchased from Cell Signaling Technology, Inc. (Beverly,
MA), and anti–b-actin antibody was purchased from Sigma-
Aldrich, Inc. (St. Louis, MO). Horseradish peroxidase
(HRP)–conjugated secondary antibodies were purchased
from Jackson Immunoresearch, Inc. (West Grove, PA). Re-
combinant human HGF was purchased from R&D Systems
(Minneapolis, MN), and the PI3K inhibitor LY294002 was
purchased from Calbiochem (La Jolla, CA). The c-Met–
specific inhibitor PHA665752 [15] was generously provided
by James Christensen, PhD (Pfizer, Inc., La Jolla, CA).
Immunoblotting
Cultured cells were serum-starved for 24 hours, treated
with various concentrations of PHA665752 or LY294002 for
2 hours, and stimulated with HGF (50 ng/ml) for 10 minutes.
Protein was extracted using lysis buffer (Cell Signaling Tech-
nology, Inc.) containing 1 mM phenylmethylsulfonylfluoride
(Sigma-Aldrich, Inc.) and quantified using the BCA protein
assay kit (Pierce, Rockford, IL). Proteins were resolved using
sodium dodecyl sulfate (SDS) polyacrylamide gels and sub-
sequently transferred to nitrocellulose membranes (Bio-Rad,
Hercules, CA). Membranes were blocked in 5%milk solution,
incubated with primary antibody, washed, and incubated with
HRP-conjugated secondary antibody. Immunoreactivity
was detected using Supersignal West Pico Chemilumines-
cent Substrate (Pierce) and X-ray film (Eastman Kodak,
Rochester, NY). Blots were stripped with 2% SDS, 100 mM
b-mercaptoethanol, and 62.5 mM (pH 6.8) Tris (Sigma-
Aldrich, Inc.) for 20 minutes at 53jC and reprobed with con-
trol antibody. Each presented immunoblot was selected
as a reproducible representative of a minimum of three indi-
vidual experiments.
Cell Viability and Apoptosis Assays
Cultured cells were serum-starved and treated with HGF
(50 ng/ml), alone and in combination with LY294002 (25 mM),
or various concentrations of PHA665752 for 24 to 72 hours.
For assessment of cell viability, 10% (vol/vol) MTT reagent
(Sigma-Aldrich, Inc.) was added to the culture, and incubation
continued for 4 hours. The medium was subsequently as-
pirated, cells were resuspended in dimethylsulfoxide (Sigma-
Aldrich, Inc.), and absorbance was recorded at 570 nm
with a SpectraMAX 340 spectrophotometer (Molecular De-
vices, Sunnyvale, CA). Absorbance was normalized to un-
treated controls and is presented as the mean ± standard
error of themean (SEM) of two to four individual experiments.
For apoptosis analysis, cells were harvested and stained
using the Annexin V–FITC apoptosis detection kit (BD Bio-
sciences, San Diego, CA), according to the manufacturer’s
instructions. Apoptosis was assessed by flow cytometry
using a Becton Dickinson FACSort (Becton Dickinson, San
Jose, CA).
Cell Wounding and In Vitro Invasion Assays
For wounding assay, cells were grown to confluence and
serum-starved for 24 hours, wounded with a pipette tip, and
treated with HGF (50 ng/ml) alone and in combination with
either LY294002 (25 mM) or various concentrations of
PHA665752. Cells were examined by light microscopy
24 hours later for the ability to repopulate the wound. For
analysis of invasion, cells were serum-starved for 24 hours,
resuspended in serum-free medium containing either
PHA665752 (at various concentrations) or LY294002 (25 mM),
and seeded at 50,000 cells/well into QCM cell invasion
assay inserts (Chemicon International, Temecula, CA). The
medium containing serum and HGF (50 ng/ml) served as a
chemoattractant in the lower chamber. Invasive cells were
detached from the undersurface of the inserts and lysed
36 hours later according to the manufacturer’s instructions.
Fluorescence was recorded at 480/520 nm using a Spectra-
Max Gemini XS fluorescence microplate reader (Molecular
Devices). Data are presented as the mean ± SEM of three
individual experiments.
Statistical Analysis
All data were checked for distributional properties by es-
timating Box–Cox transformation parameters. Both log and
square root transformations were applied, as required, to
improve symmetry and to stabilize variances. Analyses were
conducted by parametric two-way and three-way analyses
of variance. Individual contrasts were tested with either an
F test for contrasts involving three or more groups or a t-test
for two-group comparisons. Dose effects were tested with
orthogonal contrasts. All tests were two-sided. Raw P values
are reported without adjustment for multiple comparisons.
Results
PHA665752 Inhibits Constitutive and HGF-Induced
Phosphorylation of c-Met
We have previously reported the activation status and
HGF responsiveness of c-Met in three EA cell lines (Seg-1,
Bic-1, and Flo-1) known to overexpress c-Met [13]. For this
study, we sought to characterize the effects of PHA665752, a
c-Met–specific small molecule inhibitor, on c-Met phosphor-
ylation [15]. We have previously shown the constitutive
phosphorylation of c-Met in all of these cell lines by immuno-
blotting with prolonged exposure and immunofluorescence
[13]. Using short exposure to facilitate the observation of
differences in band intensity between treatments and tomake
comparisons between cell lines, a detectable level of the
constitutive phosphorylation of c-Met is observed in the Bic-1
cell line, and c-Met phosphorylation was induced by HGF in
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all threeEA cell lines (Figure 1A). Treatment with PHA665752
inhibited either constitutive (Bic-1) or HGF-induced (all three
EA cell lines) phosphorylation of c-Met in a dose-dependent
manner (Figure 1A). Prolonged exposure of an anti–c-Met
immunoblot using lysates from Flo-1 cells shows that abro-
gation of identifiable phosphorylated c-Met is technique-
dependent and that larger doses of PHA665752 may be
required to completely abolish c-Met phosphorylation
(Figure 1B). Taken together, these observations suggest that
c-Met is phosphorylated in all three EA cell lines in response
to HGF and that PHA665752 is a viable strategy to inhibit
c-Met activity in EA.
c-Met Inhibition Reduces EA Cell Viability and Differentially
Induces Apoptosis
Because c-Met promotes growth and survival in some
tumor types [5], we hypothesized that inhibition of c-Met would
reduce EA cell viability and induce apoptosis. PHA665752
is appropriately applied at doses ranging from 0.1 to 2.5 mM
[15]. No significant effects on cell viability were apparent within
24 hours of treatment with HGF or PHA665752 (Figure 2A).
Following 48 hours of HGF stimulation, the number of vi-
able Bic-1 cells and, to a lesser extent, Seg-1 cells increased,
whereas HGF had no effect on Flo-1 cell viability (Figure 2, A
andB), suggesting that c-Met induces proliferation inBic-1 and
Seg-1. Treatment with 250 nM PHA665752 decreased the
number of viable Bic-1 and Flo-1 cells, whereas a similar effect
was observed in Seg-1 cells at higher doses of PHA665752
(Figure 2, A and B).
Figure 1. PHA665752 inhibits constitutive and HGF-induced phosphorylation
of c-Met. (A) Simultaneously performed representative immunoblots of
phosphorylated c-Met (p-Met) in three EA cell lines (Seg-1, Bic-1, and Flo-1)
following PHA665752 treatment (2 hours) in the presence or in the absence of
HGF stimulation (50 ng/ml for 10 minutes). Constitutive phosphorylation of
c-Met was observed in Bic-1 cells. All three EA cell lines demonstrated
phosphorylation of the mature (140 kDa) form of c-Met following HGF stimu-
lation, and phosphorylation of the precursor (170 kDa) form of c-Met was also
observed in Seg-1 cells. PHA665752 inhibited the phosphorylation of c-Met
in a dose-dependent fashion. (B) Prolonged exposure immunoblot demon-
strating that larger doses of PHA665752 are required to completely abolish
c-Met phosphorylation (Flo-1 cells).
Figure 2. Effects of c-Met inhibition on EA cell viability and apoptosis. (A) MTT
assay time course (24–72 hours) in Bic-1 cells following treatment with HGF
(50 ng/ml) or PHA665752 (0.25 M), alone and in combination. Absorbance at
570 nm is presented as the mean ± SEM of two individual experiments.
Following 48 hours of treatment, HGF resulted in a significant increase in the
number of viable cells (P = .01), whereas PHA665752 resulted in a significant
decrease in the number of viable cells (P < .001) relative to controls, even in the
presence of HGF. These effects persisted to 72 hours. (B) MTT assay of EA
cells 48 hours following treatment with HGF (50 ng/ml) or various concen-
trations of PHA665752. Absorbance was normalized to controls (% control
viability) and is presented as the mean ± SEM of four individual experiments.
The number of viable Bic-1 (P = .01) and Seg-1 (P = .05) cells, but not Flo-1
cells, increased significantly following HGF stimulation. PHA665752 (0.25 M)
reduced the number of viable Bic-1 (P < .001) and Flo-1 (P = .01) cells, and a
similar effect was observed in Seg-1 cells (P < .001) at higher doses (1.25 M).
(C) FACScan analysis of Annexin V– and propidium iodide–stained cells
48 hours following treatment with HGF (50 ng/ml), alone or in combination with
PHA665752 (250 nM shown). Positive staining for Annexin V suggests early
apoptosis (right lower quadrant). Positive staining for propidium iodide
suggests loss of membrane integrity late in apoptosis (right upper quadrant)
or due to necrosis (left upper quadrant). HGF treatment reduced the number
of apoptotic Flo-1 cells observed relative to controls but had no effect on Bic-1
(not shown) or Seg-1 (not shown) cells. PHA665752 induced apoptosis in
Flo-1 cells, but not in Bic-1 or Seg-1 cells.
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Wenext examined the effects of c-Met inhibition on EA cell
apoptosis. HGF stimulation decreased the number of early
and late apoptotic Flo-1 cells (relative to controls), whereas
treatment with PHA665752 resulted in an increase in both
apoptotic fractions (Figure 2C), suggesting that c-Met pro-
motes survival in Flo-1. Although inhibition of c-Met reduced
the number of viable Bic-1 and Seg-1 cells compared to
controls (Figure 2, A and B), treatment with PHA665752
did not induce apoptosis at the time points assessed in the
present study (Figure 2C). Cell cycle analysis indicates
that arrest is not responsible for this observation (data not
shown), suggesting that PHA665752 inhibited proliferation
rate in these two cell lines. This is further supported by the
continued growth of Bic-1 and Seg-1 cells, albeit at a slower
rate, following treatment with PHA665752 (Figure 2A). Taken
together, these findings show that c-Met inhibition variably
affects EA cell viability and apoptosis, and suggests that
differential response of EA cells to c-Met inhibition may exist.
c-Met Differentially Stimulates EA Cell Motility
and Invasion
In addition to promoting growth and survival, c-Met–
dependent signal transduction has been shown to induce
motility and invasion in some tumor types [5], and we hypoth-
esized that inhibition of c-Met would reduce EA cell motility
and invasiveness. HGF-treated A549 cells (control cells that
express levels of Met protein similar to those of EA cell lines)
[13] and Flo-1 cells demonstrated pseudopod formation
andmigration within 24 hours of wounding, whereas no effect
was observed in Seg-1 cells, even at later (72 hours) time
points (Figure 3A). Bic-1 cells do not achieve confluence in
culture and were not analyzed. PHA665752 inhibited HGF-
induced pseudopod formation and migration in both A549
and Flo-1 cells (Figure 3A), suggesting that HGF induces
motility through c-Met–dependent signaling in these two
cell lines.
We next examined the effects of c-Met inhibition on the
property of cell invasion [18]. In the absence of HGF, sub-
stantial invasion was observed only in A549 and Flo-1 cells,
whereas HGF treatment induced invasion in A549, Flo-1, and,
to a lesser extent, Seg-1 cells (Figure 3B). Interestingly, Bic-1
cells, which demonstrate strong constitutive phosphorylation
of c-Met (Figure 1), did not invade either in the absence or
in the presence of exogenous HGF (Figure 3B). PHA665752
inhibitedHGF-induced invasion inA549, Flo-1, andSeg-1 cells
(Figure 3B), suggesting that c-Met is involved in the regulation
of invasion in these three cell lines. Collectively, these ob-
servations show that HGF differentially induces EA cell motility
and invasion through c-Met signaling and further supports
the notion that cell line–specific differences exist in response
to c-Met inhibition.
c-Met Variably Modulates ERK and AKT Signaling in EA
Pleiotropic response to c-Met activationmay be explained,
in part, by diverse intracellular mediators that convey c-Met
signaling [19–21]. Because ERK and Akt are involved in
c-Met signal transduction and contribute to cell growth,
survival, motility, and invasion [22,23], we hypothesized that
c-Met differentially modulates ERK and Akt signaling in EA.
All three EA cell lines demonstrated constitutive ERK phos-
phorylation, which was further augmented following HGF
stimulation (Figure 4A). PHA665752 modestly attenuated
constitutive ERK phosphorylation in Bic-1 and Seg-1 cells
and inhibited HGF-induced ERK phosphorylation in all three
EA cell lines (Figure 4A). Although the effects of PHA665752
on constitutive ERK phosphorylation in Seg-1 cells raise the
possibility of inhibitor nonspecificity, Seg-1 cells express
HGF, and we have reported the constitutive phosphorylation
of c-Met in these cells [13]. Constitutive phosphorylation
of Akt was not observed in any of the EA cell lines, and
treatment with HGF inducedAkt phosphorylation only in Flo-1
cells (Figure 4B). Consistent with induction of activity by
HGF, Akt phosphorylation was inhibited in a dose-dependent
fashion by PHA665752 only in Flo-1 cells (Figure 4B). Taken
together, these findings demonstrate that c-Met differ-
entially modulates ERK and Akt signaling in EA cell lines
and suggest that the response of EA cells to c-Met inhibition
Figure 3. Effects of c-Met inhibition on EA cell motility and invasion. (A)
Phase-contrast light microscopy of A549 (control) cells and the EA cell lines
Flo-1 and Seg-1 24 hours following wounding. HGF (50 ng/ml) induced
pseudopod formation and motility in A549 and Flo-1 cells, but not in Seg-1
cells; PHA665752 (250-nM dose shown) inhibited these HGF-induced
effects. (B) Invasiveness of A549 (control) cells and the three EA cell lines
(Seg-1, Bic-1, and Flo-1) 36 hours following treatment with HGF (50 ng/ml),
alone or in combination with PHA665752 (250 nM dose shown). Data are
presented as mean relative fluorescence units at 480/520 nm ± SEM of three
individual experiments. HGF increased invasion in A549 (P = .0003), Seg-1
(P < .0001), and Flo-1 (P = .0001) cells. HGF-induced invasion was atten-
uated in Seg-1 cells (P = .0001) and was completely inhibited in A549 (P =
.0003) and Flo-1 (P = .0001) cells following treatment with PHA665752.
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may be dependent, at least in part, on intracellular mediators
that participate in c-Met signal transduction.
The Effects of PI3K Inhibition on Cell Survival, Motility,
and Invasion Are Similar to Those of c-Met Inhibition
in Flo-1 Cells
Because stimulation of c-Met promoted the greatest
effects on survival, motility, and invasion in Flo-1 cells, we
hypothesized that PI3K/Akt signaling mediated these HGF-
induced effects. Inhibition of PI3K with LY294002 (at doses
of z 10 mM) abolished HGF-induced phosphorylation of
Akt (Figure 5A) and resulted in an increased number of
both early and late apoptotic Flo-1 cells (Figure 5B). Com-
pared to c-Met inhibition, PI3K blockade by LY294002
was associated with a larger fraction of early apoptotic cells
(Figures 2C and 5B) and a greater inhibition of invasion
(Figure 5D), suggesting that some PI3K activity in these cells
is not c-Met–dependent. HGF-induced motility of Flo-1 cells
was similarly abrogated following both c-Met and PI3K inhi-
bition (Figures 3A and 5C). Collectively, these findings sup-
port the current opinion that PI3K/Akt signaling is critical in
the regulation of c-Met– induced survival, motility, and inva-
sion [24,25], and suggest that the effects of c-Met inhibition
on EA may be dependent, at least in part, on the involvement
and/or the dependence of the PI3K/Akt pathway on c-Met
signal transduction.
Discussion
Our earlier observation that c-Met was not expressed in
normal squamous esophagus or nondysplastic Barrett’s
esophagus but was usually overexpressed in EA [13] sup-
ports the potential for therapies that inhibit c-Met in
the treatment of EA. We have shown that HGF/c-Met–
dependent signaling differentially induces proliferation, sur-
vival, motility, and invasion, as well as ERK and Akt signaling,
in a panel of EA cell lines. Although all three EA cell lines
overexpress c-Met [13], PHA665752 induced apoptosis and
inhibited motility and invasion only in cells (Flo-1) in which
PI3K/Akt signaling was stimulated by HGF. Our findings
support the use of strategies to inhibit c-Met as a viable
therapeutic option for EA and suggest that factors other
Figure 4. Modulation of ERK and Akt signaling by c-Met. Immunoblot of (A)
phosphorylated ERK and (B) phosphorylated Akt in three EA cell lines (Seg-1,
Bic-1, and Flo-1) following PHA665752 treatment (2 hours) in the presence or
in the absence of HGF (50 ng/ml) stimulation (10 minutes). All three EA cell
lines demonstrated constitutive ERK phosphorylation, and HGF induced
further phosphorylation of ERK. PHA665752 attenuated constitutive ERK
phosphorylation in Seg-1 cells and inhibited HGF-induced ERK phosphor-
ylation in Seg-1 and Flo-1 cells; lesser effects were observed in Bic-1 cells at
the highest dose of PHA665752. Conversely, constitutive phosphorylation of
Akt was not observed in any of the EA cell lines. HGF induced Akt phos-
phorylation only in Flo-1 cells, and this was inhibited by PHA665752 in a dose-
dependent fashion.
Figure 5. Effects of PI3K inhibition compared to c-Met inhibition. (A)
Immunoblot of phosphorylated Akt in Flo-1 cells following LY294002 treat-
ment (2 hours) in the presence or in the absence of HGF (50 ng/ml)
stimulation (10 minutes). Akt phosphorylation was abolished following
treatment with LY294002 at concentrations of z 10 M. (B) FACScan
analysis of Annexin V– and propidium iodide–stained Flo-1 cells 48 hours
following treatment with HGF (50 ng/ml) in combination with LY294002
(25 M). Treatment with LY294002 resulted in apoptosis. (C) Light microscopy
of Flo-1 cells 24 hours following wounding. HGF (50 ng/ml) induced pseudo-
pod formation and migration, which was inhibited by LY294002 (25 M). (D)
Invasiveness of A549 (control) and Flo-1 cells 36 hours following treatment with
HGF (50 ng/ml), alone or in combination with either PHA665752 (250-nM dose
shown) or LY294002 (25 M). Data are presented as mean relative
fluorescence units at 480/520 nm ± SEM of three individual experiments.
HGF induced invasion in A549 (P = .0003) and Flo-1 (P = .0001) cells, which
was inhibited by both PHA665752 (A549, P = .0003; Flo-1, P = .0001) and
LY294002 (A549, P = .0001; Flo-1, P < .0001). Treatment with LY294002
further reduced invasion below basal levels in Flo-1 (P < .001) cells.
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than overexpression of c-Met, such as involvement of PI3K/
Akt in c-Met signal transduction, may determine the response
of an individual neoplasm to c-Met inhibition.
Observations in various tumor models [5] suggest that
c-Met signaling induces pleiotropic effects, yet few studies
have examined this phenomenon in a panel of cell lines
derived from the same tumor type. Similar to our findings,
Coltella et al. [26] observed differential responses to c-Met
stimulation in five osteosarcoma cell lines that overexpress
c-Met. Treatment with HGF induced proliferation and ERK
phosphorylation in four of the cell lines, stimulated motility/
invasion and Akt phosphorylation in two of the cell lines, and
had no effect in one cell line. Additionally, differential effects
of c-Met inhibition on anchorage-independent growth have
been reported in panels of cell lines derived from lung and
gastric cancers, as well as in gliomas [15]. In contrast, Miller
et al. [14] recently demonstrated global induction of apoptosis
following treatment with the heat shock protein 90 (Hsp90)
inhibitor geldanamycin in the same three EA cell lines used in
our study; however, the specificity of this response for c-Met
is unclear as Hsp90 is involved in signal transduction from a
variety of tyrosine kinase receptors [3,27]. Similar to our
observations in EA, these studies suggest that the response
of other neoplasms to c-Met inhibition therapy may also be
dependent on factors other than receptor overexpression.
Although our findings suggest that optimal response to
c-Met inhibition will be observed in cells that signal through
PI3K/Akt, other possibilities should be considered. Similar to
other receptor tyrosine kinase–targeted therapies, such as
Herceptin, Gleevec, and Iressa, the most robust clinical
response may be observed in patients with genetic alteration
(mutation and gene amplification) of their intended target
[28–30]. Although genomic amplification of met has been
reported in EA, met is not amplified in the three EA cell lines
used in this study [14], and we have previously reported that
the c-Met kinase domain is not mutated in these three EA cell
lines [13]. Consequently, these in vitro EA models do not
allow the determination of whether genomic alterations inmet
impact the response of EA to c-Met inhibition.
Constitutive activation of c-Met has been correlated with
PI3K-dependent cell survival in NSCLC cell lines [31], sug-
gesting that the most robust response to c-Met inhibition
may be expected in cells with constitutive c-Met activity. We
did not observe constitutive or HGF-induced activation of
PI3K/Akt (Figure 4B) in the EA cell line with basal activation
of c-Met (Bic-1; Figure 1), and inhibition of c-Met did not
induce apoptosis in this cell line (Figure 2C). Bic-1 cells ex-
press HGF [13], suggesting that autocrine activation is likely,
whereas an HGF-independent mechanism is responsible
for c-Met activation in NSCLC cell lines [31] and may account
for these differences.
The mechanism(s) responsible for the differential involve-
ment of PI3K/Akt signaling in c-Met signal transduction
requires further investigation. Our findings aremost consistent
with differential recruitment of adaptor proteins, such asGab1,
to the carboxy-terminal docking site of c-Met, and we intend
to perform further experiments to test this hypothesis. Alter-
natively, the PTEN (phosphatase and tensin homologue de-
leted in chromosome 10) tumor-suppressor protein is one of
the most widely studied inhibitors of PI3K [32], and PTEN loss
has been associated with resistance to other forms of tyro-
sine kinase inhibition therapy [33–35]. However, loss of PTEN
function is generally associated with constitutive PI3K activity
[36], and PTEN mutation has not been identified in over
80 samples of EA [37], suggesting that loss of PTEN is unlikely
to be responsible for our observations.
Two limitations of this study are the lack of a molecular
method of blocking c-Met function and the lack of an in vivo
model. The specificity of PHA665752 for c-Met has been
previously established [15], and off-target effects are gen-
erally not seen at doses less than 2 mM (J. G. Christensen,
personal communication), suggesting that effects are c-Met–
specific. Furthermore, PHA665752 has been compared with
other techniques of c-Met inhibition (anti-HGF antibody and
c-Met RNA inhibition), and its effects have been shown to be
c-Met–dependent [38]. Molecular HGF/c-Met inhibition strat-
egies [8,39–41] and other strategies including HGF antago-
nists or neutralizers [42–45], c-Met dimerization blockers
[46–49], and inhibitors of the c-Met intracellular pathway
[20] have been reported. Phosphorylation of a catalytic do-
main (Tyr1230/1234/1235) is believed to be required for c-Met
signaling [21]. Thus, unlike these other inhibition strategies,
one advantage of our approach is that PHA665752 should in-
hibit the HGF/c-Met pathway irrespective of the mechanism
of activation. Unfortunately, PHA665752 causes vein sclero-
sis and peritonitis in mice precluding in vivo experimentation.
In summary, our study is the first to investigate the effects
of a c-Met–specific inhibitor on EA. Using a panel of c-Met–
overexpressing EA cell lines, we have demonstrated vari-
ability in the response of EA to c-Met inhibition that correlated
with downstream pathway activation. Our data support c-Met
inhibition as a potential therapy for EA.
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